DBRC
VRTX icon

D.B. Root & Company’s Vertex Pharmaceuticals VRTX Stock Holding History

D.B. Root & Company’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$292K Sell
654
-159
-20% -$74.1K 0.07% 156
2025
Q4 		$369K Sell
813
-144
-15% -$62.1K 0.09% 134
2025
Q3 		$375K Sell
957
-125
-12% -$52.2K 0.1% 129
2025
Q2 		$482K Sell
1,082
-27
-2% -$12.4K 0.14% 107
2025
Q1 		$538K Buy
1,109
+242
+28% +$113K 0.17% 95
2024
Q4 		$349K Sell
867
-44
-5% -$20.4K 0.11% 129
2024
Q3 		$424K Sell
911
-124
-12% -$59.6K 0.14% 105
2024
Q2 		$485K Sell
1,035
-359
-26% -$156K 0.17% 109
2024
Q1 		$583K Buy
1,394
+26
+2% +$11K 0.2% 103
2023
Q4 		$557K Sell
1,368
-162
-11% -$59.8K 0.2% 105
2023
Q3 		$532K Sell
1,530
-12
-0.8% -$4.2K 0.21% 107
2023
Q2 		$543K Buy
1,542
+57
+4% +$19.2K 0.21% 107
2023
Q1 		$468K Buy
1,485
+20
+1% +$6K 0.18% 111
2022
Q4 		$423K Sell
1,465
-28
-2% -$8.53K 0.18% 114
2022
Q3 		$432K Buy
1,493
+183
+14% +$52.7K 0.2% 109
2022
Q2 		$369K Sell
1,310
-1,964
-60% -$526K 0.16% 126
2022
Q1 		$854K Sell
3,274
-595
-15% -$141K 0.32% 78
2021
Q4 		$849K Sell
3,869
-64
-2% -$12.4K 0.31% 81
2021
Q3 		$713K Sell
3,933
-770
-16% -$150K 0.28% 101
2021
Q2 		$948K Sell
4,703
-64
-1% -$13.4K 0.35% 74
2021
Q1 		$1.02M Buy
4,767
+2,348
+97% +$516K 0.4% 59
2020
Q4 		$571K Buy
+2,419
New +$555K 0.23% 111
2020
Q1 		– Sell
-1,375
Closed -$301K – 205
2019
Q4 		$301K Sell
1,375
-15
-1% -$3.04K 0.13% 167
2019
Q3 		$235K Sell
1,390
-780
-36% -$138K 0.11% 175
2019
Q2 		$397K Buy
2,170
+455
+27% +$79.5K 0.18% 138
2019
Q1 		$315K Buy
1,715
+135
+9% +$24.9K 0.13% 171
2018
Q4 		$262K Sell
1,580
-189
-11% -$32.7K 0.13% 163
2018
Q3 		$341K Buy
1,769
+154
+10% +$27.4K 0.15% 160
2018
Q2 		$274K Buy
1,615
+30
+2% +$4.65K 0.13% 171
2018
Q1 		$258K Buy
+1,585
New +$259K 0.14% 167

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

D.B. Root & Company's VRTX Position: Q1 2026 in Review

D.B. Root & Company reduced its Vertex Pharmaceuticals (VRTX) stake by 20% in Q1 2026, selling an estimated $74.1K and leaving 654 shares worth $292K. The position accounts for 0.07% of the portfolio, ranked #156.

D.B. Root & Company first reported a position in VRTX in Q1 2018 and has held it in 30 quarters since. The position peaked at $1.02M in Q1 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • D.B. Root & Company held 654 shares of Vertex Pharmaceuticals worth $292K as of Q1 2026.
  • D.B. Root & Company sold 159 Vertex Pharmaceuticals shares in Q1 2026, an estimated $74.1K.
  • Vertex Pharmaceuticals made up 0.07% of D.B. Root & Company's portfolio in Q1 2026, its #156 holding.
  • D.B. Root & Company first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 30 quarters since.
  • D.B. Root & Company's Vertex Pharmaceuticals position peaked at $1.02M in Q1 2021.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on D.B. Root & Company's 13F filing for Q1 2026, filed 13 May 2026.